TGFB1 and pancreatic neoplasm: Treatment involving HCW9218, a bifunctional TGF-β antagonist showing IL-15 immunostimulatory activity, can increase the antitumor activity of chemotherapy nab-paclitaxel and gemcitabine and prolong the survival of pancreatic tumor-bearing mice [122].